Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.08 · Revenue $12.00M · 2 analysts
Est. EPS $-0.44 · Revenue $0.00 · 2 analysts
Est. EPS $-0.67 · Revenue $12.00M · 2 analysts
Est. EPS $-0.03 · Revenue $0.00 · 1 analysts
EPS $-1.41 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-75.8M | -6.4% | -135.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-77.2M | -22.2% | +52.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 29.8% | +912.1% | -14.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.62x | -47.2% | -34.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $35.8M | -55.2% | -44.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.95 vs -4.38 | +9.8% | -0.10 vs -0.08 | -25.0% |
| Revenue Surprise | $0 vs $4.4M | -100.0% | $0 vs $12.0M | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | WIGGANS THOMAS G | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | Lucas Svetlana | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | Crutcher Patrick J | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | EMSTER KURT VON | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | Shizuru Judith Anne | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Matthew E. Ros | Chief Operating Officer | USD 665,399 | Male | 1967 | Active |
Jeetinder Singh Mahal | President, Chief Executive Officer & Director | USD 610,050 | Male | 1972 | Active |
Herbert C. Cross | Chief Financial Officer & Corporate Secretary | USD 603,925 | Male | 1972 | Active |
Thomas G. Wiggans | Executive Chairman | USD 70,000 | Male | 1952 | Active |
Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director | USD 46,300 | — | 1956 | Active |
Luca Di Noto | Senior Vice President of Technical Operations | — | — | — | Active |
Alex Gray | Head of Investor Relations | — | — | — | Active |
Matthew Ford | Senior Vice President of Human Resources | — | Male | — | Active |
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Kira Pharmaceuticals, bringing the two biotechnology companies together to advance a unified pipeline of therapies targeting immune-mediated and autoantibody-driven diseases.
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value.
